Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;31(3):345-365.
doi: 10.1007/s10557-017-6736-z.

MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications

Affiliations

MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications

Nicoline W E van den Berg et al. Cardiovasc Drugs Ther. 2017 Jun.

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with pronounced morbidity and mortality. Its prevalence, expected to further increase for the forthcoming years, and associated frequent hospitalizations turn AF into a major health problem. Structural and electrical atrial remodelling underlie the substrate for AF, but the exact mechanisms driving this remodelling remain incompletely understood. Recent studies have shown that microRNAs (miRNA), short non-coding RNAs that regulate gene expression, may be involved in the pathophysiology of AF. MiRNAs have been implicated in AF-induced ion channel remodelling and fibrosis. MiRNAs could therefore provide insight into AF pathophysiology or become novel targets for therapy with miRNA mimics or anti-miRNAs. Moreover, circulating miRNAs have been suggested as a new class of diagnostic and prognostic biomarkers of AF. However, the origin and function of miRNAs in tissue and plasma frequently remain unknown and studies investigating the role of miRNAs in AF vary in design and focus and even present contradicting results. Here, we provide a systematic review of the available clinical and functional studies investigating the tissue and plasma miRNAs in AF and will thereafter discuss the potential of miRNAs as biomarkers or novel therapeutic targets in AF.

Keywords: Atrial fibrillation; Electrical remodelling; Fibrosis; Therapy; microRNA.

PubMed Disclaimer

Conflict of interest statement

J.R. de Groot received a grant from NWO/ZonMW(106.146.310). A.J. Tijsen received a grant from NWO/ZonMW(016.166.150). To the best of our knowledge, no conflict of interest, financial or other, exists for the co-authors. This article does not contain any original studies with human participants or animals performed by any of the authors. There were no human cases included and thus no informed consent was needed.

Figures

Fig. 1
Fig. 1
microRNAs expressed in plasma and tissue. This figure illustrates the number of miRNAs differentially expressed in tissue and in plasma in AF patients. Note the high number of upregulated miRNAs in tissue, whereas miRNAs in plasma more often have lower levels in AF. Furthermore, there is little overlap between tissue and plasma expression of the miRNAs that have lower or higher levels in AF (between the dotted lines). There is a substantial proportion of miRNAs that present contradicting results (miRNAs described to be both up- and downregulated in tissue or plasma)

Similar articles

Cited by

References

    1. Ball J, Carrington MJ, McMurray JJV, et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167:1807–1824. doi: 10.1016/j.ijcard.2012.12.093. - DOI - PubMed
    1. Chen LY, Shen W-K. Epidemiology of atrial fibrillation: a current perspective. Hear Rhythm Off J Hear Rhythm Soc. 2007;4:S1–S6. doi: 10.1016/j.hrthm.2006.12.018. - DOI - PubMed
    1. Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114:1453–1468. doi: 10.1161/CIRCRESAHA.114.303211. - DOI - PubMed
    1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)developed with the special contribution of the Europea. Eur Heart J 2016;:ehw210.
    1. Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterisation, and clinical implication. 2016. - PMC - PubMed

Publication types